Intrathecal Corticosteroids Might Slow Alzheimer's Disease Progression

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2009 Feb 3

PMID 19183775

Citations 9

Authors

Joseph Martin Alisky

Affiliations

Soon will be listed here.

Abstract

Anti-inflammatory drugs for treatment and prevention of Alzheimer's disease have to date proved disappointing, including a large study of low-dose prednisone, but higher dose steroids significantly reduced amyloid secretion in a small series of nondemented patients. In addition, there is a case report of a patient with amyloid angiopathy who had complete remission from two doses of dexamethasone, and very high dose steroids are already used for systemic amyloidosis. This paper presents the hypothesis that pulse-dosed intrathecal methylprednisolone or dexamethasone will produce detectable slowing of Alzheimer's progression, additive to that obtained with cholinesterase inhibitors and memantine. A protocol based on treatment regimens for multiple sclerosis and central nervous system lupus is outlined, to serve as a basis for formulating clinical trials. Ultimately intrathecal corticosteroids might become part of a multi-agent regimen for Alzheimer's disease and also have application for other neurodegenerative disorders.

Citing Articles

Effect of Steroids on the Progression of Alzheimer's Dementia: A Retrospective Chart Review.

Conic J, Chetty A, Chen L, Marsh A, Barry S, Pattabhi R Aging Med (Milton). 2025; 8(1):e70004.

PMID: 39968005 PMC: 11833297. DOI: 10.1002/agm2.70004.

In Search for Low-Molecular-Weight Ligands of Human Serum Albumin That Affect Its Affinity for Monomeric Amyloid β Peptide.

Deryusheva E, Shevelyova M, Rastrygina V, Nemashkalova E, Vologzhannikova A, Machulin A Int J Mol Sci. 2024; 25(9).

PMID: 38732194 PMC: 11084196. DOI: 10.3390/ijms25094975.

The Effect of Different Concentrations of Methylprednisolone on Survival, Proliferation, and Migration of Neural Stem/Progenitor Cells.

Bagheri Z, Shamsi F, Zeraatpisheh Z, Salmannejad M, Soltani A, Aligholi H Basic Clin Neurosci. 2022; 13(2):207-213.

PMID: 36425947 PMC: 9682315. DOI: 10.32598/bcn.2021.35.4.

Mining on Alzheimer's diseases related knowledge graph to identity potential AD-related semantic triples for drug repurposing.

Nian Y, Hu X, Zhang R, Feng J, Du J, Li F BMC Bioinformatics. 2022; 23(Suppl 6):407.

PMID: 36180861 PMC: 9523633. DOI: 10.1186/s12859-022-04934-1.

Deep phenotyping of Alzheimer's disease leveraging electronic medical records identifies sex-specific clinical associations.

Tang A, Oskotsky T, Havaldar S, Mantyh W, Bicak M, Warly Solsberg C Nat Commun. 2022; 13(1):675.

PMID: 35115528 PMC: 8814236. DOI: 10.1038/s41467-022-28273-0.

References

Hellwig K, Stein F, Przuntek H, Muller T . Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol. 2004; 4(1):18. PMC: 535343. DOI: 10.1186/1471-2377-4-18. View

Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24. DOI: 10.1001/jama.291.3.317. View

Marynick S, Havens 2nd W, EBERT M, Loriaux D . Studies on the transfer of steroid hormones across the blood-cerebrospinal fluid barrier in the Rhesus Monkey. Endocrinology. 1976; 99(2):400-5. DOI: 10.1210/endo-99-2-400. View

Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N, Przuntek H . Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Clin Neuropharmacol. 2006; 29(5):286-91. DOI: 10.1097/01.WNF.0000229545.81245.A4. View

Mrak R, Griffin W . Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis. 2006; 8(4):369-75. DOI: 10.3233/jad-2005-8406. View

Funauchi M, Ohno M, Nozaki Y, Sugiyama M, Kinoshita K, Kanamaru A . Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. J Rheumatol. 2003; 30(1):207-8. View

Varney N . A case of reversible steroid dementia. Arch Clin Neuropsychol. 1997; 12(2):167-71. View

Lee H, Zhu X, Nunomura A, Perry G, Smith M . Amyloid beta: the alternate hypothesis. Curr Alzheimer Res. 2006; 3(1):75-80. DOI: 10.2174/156720506775697124. View

van Gool W, Weinstein H, Scheltens P, Walstra G, Scheltens P . Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001; 358(9280):455-60. DOI: 10.1016/s0140-6736(01)05623-9. View

10.

Aisen P, Davis K, Berg J, Schafer K, Campbell K, Thomas R . A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000; 54(3):588-93. DOI: 10.1212/wnl.54.3.588. View

11.

Jacobsson J, Persson M, Hansson E, Ronnback L . Corticosterone inhibits expression of the microglial glutamate transporter GLT-1 in vitro. Neuroscience. 2006; 139(2):475-83. DOI: 10.1016/j.neuroscience.2005.12.046. View

12.

McGeer P, Rogers J, McGeer E . Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006; 9(3 Suppl):271-6. DOI: 10.3233/jad-2006-9s330. View

13.

Cagnin A, Kassiou M, Meikle S, Banati R . In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl. 2006; 185:107-14. DOI: 10.1111/j.1600-0404.2006.00694.x. View

14.

Dhodapkar M, Hussein M, Rasmussen E, Solomon A, Larson R, Crowley J . Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004; 104(12):3520-6. DOI: 10.1182/blood-2004-05-1924. View

15.

Endoh M, Kunishita T, Tabira T . No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and beta-amyloid neurotoxicity. J Neurol Sci. 1999; 165(1):28-30. DOI: 10.1016/s0022-510x(99)00057-x. View

16.

Wojtera M, Sikorska B, Sobow T, Liberski P . Microglial cells in neurodegenerative disorders. Folia Neuropathol. 2006; 43(4):311-21. View

17.

Keimowitz R . Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma. Arch Neurol. 1997; 54(4):485-8. DOI: 10.1001/archneur.1997.00550160111024. View

18.

Town T, Nikolic V, Tan J . The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation. 2005; 2:24. PMC: 1298325. DOI: 10.1186/1742-2094-2-24. View

19.

Sacks O, Shulman M . Steroid dementia: an overlooked diagnosis?. Neurology. 2005; 64(4):707-9. DOI: 10.1212/01.WNL.0000151977.18440.C3. View

20.

Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P . Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006; 27(1):33-9. DOI: 10.1007/s10072-006-0562-6. View